Clay Siegall’s Input in the Production of Medicines

Clay Siegall, a scientist by training, is the co-founder as well as the company president of the Seattle Genetics. He pursued his education at the University of Maryland where he took a degree course in Bachelor of Science Zoology. He also studied at the George Washington University where he took a Doctor of Philosophy (Ph. D) in Genetics. After completing his studies, the scientist worked with the National Cancer Institute, National Institutes of Health between 1988 and 1991 then Bristol-Myers Squibb Pharmaceutical Research Institute between 1991 and 1997.

Dr. Siegall built Seattle Genetics upon the pillars of in-depth research, scientific innovation, a passion for helping patients and drug development practices. He then became the Chief Executive Officer and the Chairman of the board, positions which have enabled him to drive the company towards developing ADCs- Antibody Drug Conjugates for the treatment of cancer. The company has acquired licenses in the production of ADCs on many scales such as with GlaxoSmithKline, Pfizer and Genentech (Roche). Through this, they have so far made about $300 million. The doctor has also led the company towards acquiring about $675 million through financing by the private and public sector. By his efforts, Dr. Siegall has been given many awards such as the 2013 University of Maryland Alumnus of the Year for Computer, Math and Natural sciences as well as the 2012 Pacific Northwest Ernst and Young Entrepreneur of the Year. Dr. Siegall has authored more than 70 publications and has about 15 patents to his name.

At Seattle Genetics, development of drugs is as a result of intense study that has been undertaken. The drugs are, therefore, powerful enough to destroy a cancer cell from inside. This strategy should drive the company to the crème of medicine development. The company has already become the largest biotech company in Washington. Clay Siegall points out that the company is a fast rising oncology company. The ambitions and desire of Siegall to grow the company beyond its current position are out of question. They aim to further increase the way they handle all the international marketing complexities.

The biotech company has made major steps in growth in recent days. The valuation of the company has risen by more than 50%. In 2016, they made sales of nearly $418 million, which was a rise of about 46% from two years before. It is thought that the current rise in business could be as a result of the intense research and investment pout into production.

Leave a Reply

Your email address will not be published. Required fields are marked *